rs3754048 — APH1A -980C/G

Regulatory variant 2 kb upstream of APH1A where the C allele (paper's G, coding strand) increases YY1 transcription factor binding and drives ~2.7-fold higher APH1A transcription, elevating gamma-secretase activity, increasing Aβ42 production, and raising Alzheimer's disease risk.

See your personal result for APH1A

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

APH1A Promoter Variant — Elevated Gamma-Secretase Activity and Alzheimer's Risk

A regulatory variant 2 kb upstream of APH1A sits at the molecular origin of amyloid precursor protein (APP) cleavage. APH1A11 APH1A
anterior pharynx-defective 1A, a seven-transmembrane scaffolding subunit of the gamma-secretase complex is an obligate structural component of the enzyme that cuts APP into fragments, including the neurotoxic Aβ42 peptide — the primary driver of amyloid plaque formation in Alzheimer's disease. rs3754048 is a single-nucleotide change in the APH1A promoter region where one allele creates a stronger binding site for the YY122 YY1
Yin Yang 1, a transcription factor that can activate or repress gene expression depending on context and co-factors transcription factor, switching on higher APH1A production and consequently greater gamma-secretase activity.

The Mechanism

APH1A is on the minus strand of chromosome 1. The variant described as -980C/G in the literature (coding-strand notation) corresponds to G>C on the GRCh38 plus strand. The C allele (plus strand) — the paper's coding-strand G — creates an enhanced YY1 binding site in the APH1A promoter. Qin et al. 201133 Qin et al. 2011
Qin W et al. The -980C/G polymorphism in APH-1A promoter confers risk of Alzheimer's disease. Aging Cell. 2011 demonstrated this through electrophoretic mobility shift assay (EMSA): the C allele binds YY1 more avidly, and YY1 overexpression activates the APH1A promoter 2.7-fold in both N2A neuroblastoma and HEK293 cells. The consequence is measurably higher APH1A protein levels and elevated gamma-secretase activity in individuals carrying the C allele, which shifts APP cleavage toward more Aβ42 production.

The connection to sleep runs through Aβ's role as a circadian regulator. Soluble Aβ oscillates with the sleep-wake cycle — levels are highest during waking and fall during sleep as the glymphatic system44 glymphatic system
the brain's cerebrospinal-fluid-driven waste-clearance network, most active during slow-wave sleep flushes it. Elevated gamma-secretase activity from the C allele increases the baseline Aβ load that the glymphatic system must clear each night. Over decades, even a modest increase in production can tip the balance toward accumulation, particularly during periods of sleep disruption.

The Evidence

The association between rs3754048 and Alzheimer's disease was first reported by Wang & Jia 200955 Wang & Jia 2009
Wang Y, Jia J. Association between promoter polymorphisms in anterior pharynx-defective-1a and sporadic Alzheimer's disease in the North Chinese Han population. Neurosci Lett. 2009 in 256 sporadic Alzheimer's disease patients and 276 controls from North China. The coding-strand G genotype and G allele were significantly more frequent in AD cases (genotype P=0.038, allele P=0.01 in the full cohort; genotype P=0.048, allele P=0.016 in APOE ε4-positive subjects). The interaction with APOE ε4 suggests an additive or synergistic risk pathway.

The functional basis for this association was established by Qin et al. 201166 Qin et al. 2011
Qin W et al. The -980C/G polymorphism in APH-1A promoter confers risk of Alzheimer's disease. Aging Cell. 2011, which validated the association in two additional Chinese cohorts (450 AD and 450 controls in the replication arm) and provided the mechanistic data: YY1-driven 2.7-fold promoter activation, increased APH1A protein expression, and elevated gamma-secretase activity measured in carrier tissue samples. Evidence is graded moderate: the studies are replicated and the functional mechanism is clear, but both cohorts are Chinese, sample sizes are modest by modern GWAS standards, and no large-scale multi-ancestry replication exists.

The sleep dimension is supported by complementary evidence. Lim et al. 201477 Lim et al. 2014
Lim MM et al. The sleep-wake cycle and Alzheimer's disease: what do we know? Neurodegener Dis Manag. 2014 established the reciprocal loop: as Aβ accumulates, sleep-wake fragmentation worsens; as sleep quality degrades, glymphatic clearance falls and Aβ accumulates faster. Wu et al. 201988 Wu et al. 2019
Wu H et al. The role of sleep deprivation and circadian rhythm disruption as risk factors of Alzheimer's disease. Front Neuroendocrinol. 2019 extended this to circadian disruption, showing that clock misalignment impairs the glymphatic-vascular-lymphatic clearance of Aβ and tau, reduces melatonin, and increases neuronal oxidative stress. For APH1A C-allele carriers, this means the upstream production tap is open wider — making sleep quality and circadian alignment more consequential than for the general population.

Practical Actions

The APH1A C allele does not cause Alzheimer's disease; it shifts the balance of the gamma-secretase complex toward higher Aβ42 output. Practical interventions for C-allele carriers focus on two complementary strategies: protecting glymphatic clearance of Aβ during sleep, and monitoring amyloid-sensitive biomarkers to detect accumulation early. The evidence for melatonin as a specific intervention in APH1A-variant carriers comes from the circadian-amyloid literature rather than direct trials in this genotype, so it is graded accordingly.

Interactions

rs3754048 interacts with APOE ε4 status (rs429358). Wang & Jia 2009 found the association strengthened in APOE ε4-positive subjects — the two risk factors appear to act in the same downstream pathway (Aβ production and clearance) and may have super-additive effects. rs34714364 is the related APH1A/CA14 locus chronotype variant already in the GeneOps database; it tags regulatory variation at the APH1A locus affecting circadian preference, while rs3754048 is the directly functional promoter variant affecting gamma-secretase activity. These two APH1A-locus variants complement each other for a complete picture of APH1A-mediated Alzheimer's and sleep pathology risk.

Genotype Interpretations

What each possible genotype means for this variant.

GG Standard Gamma-Secretase Activity Normal

Common genotype — baseline APH1A expression and gamma-secretase activity

You carry two copies of the common G allele at rs3754048. On the plus strand, G is the GRCh38 reference allele and corresponds to the lower-YY1-binding form of the APH1A promoter. About 41% of people globally share this genotype; in European populations, roughly 50% carry GG. Your APH1A expression and gamma-secretase activity are at the population baseline for this locus, meaning APP cleavage to Aβ42 is not elevated by this specific variant.

CG Elevated Gamma-Secretase Activity Intermediate

One C allele — moderately elevated APH1A expression and Alzheimer's risk signal

APH1A encodes a required structural component of the gamma-secretase complex. Higher APH1A expression means more active enzyme complexes available to cleave amyloid precursor protein (APP) into Aβ42 fragments. Qin et al. 2011 showed that the coding-strand G allele (plus-strand C) increases YY1-driven APH1A transcription 2.7-fold in cell experiments, with measurably higher APH1A protein and gamma-secretase activity in human tissue samples from carriers.

The additive inheritance pattern means GC heterozygotes have an intermediate increase in expression compared to GG. The clinical significance is a moderate increase in Alzheimer's risk, particularly in combination with APOE ε4 (rs429358). The connection to sleep is mechanistic: higher Aβ42 production means more amyloid must be cleared nightly by the glymphatic system, raising the stakes of any sleep disruption.

CC High Gamma-Secretase Activity High Risk

Two C alleles — highest APH1A expression and elevated Alzheimer's risk at this locus

CC homozygotes have both copies of the APH1A promoter in the high-transcription configuration. Qin et al. 2011 demonstrated a 2.7-fold activation of the APH1A promoter when YY1 — the transcription factor that binds preferentially to the C-allele (coding-strand G) site — is overexpressed. In vivo, this translates to higher APH1A protein levels, more assembled gamma-secretase complexes, and greater APP cleavage toward Aβ42 production.

The Wang & Jia 2009 study found a statistically significant enrichment of the G genotype (plus-strand CC) in sporadic Alzheimer's cases versus controls (P=0.038 for genotype, P=0.01 for allele), with the effect amplified in APOE ε4-positive subjects (P=0.048 / P=0.016). This suggests APH1A and APOE ε4 act on the same Aβ production-clearance axis and their risk contributions are at minimum additive.

The amyloid-sleep feedback loop (Lim et al. 2014) means that the elevated baseline Aβ42 production from CC creates a narrower margin for sleep disruption: less clearance capacity is needed to maintain balance, and any chronic sleep fragmentation or short sleep tips the system toward accumulation faster than in GG individuals. Melatonin supplementation has independent evidence as a modulator of gamma-secretase activity and Aβ clearance in animal models and small human trials, providing a specific rationale for consideration in high-APH1A-activity carriers.